Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Solarboom 2024: Fünf Gründe, die für diese Aktie sprechen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
710 Leser
Artikel bewerten:
(2)

Webinar on Healthcare Innovations for Sustainable Future by Kalkine Media on October 21, 2021

SYDNEY, Oct. 16, 2021 /PRNewswire/ -- Ensuring healthy lives and promoting physical and mental well-being is essential to sustainable development. Currently, the world is facing a global health crisis unlike any other. Global health has increasingly gained international visibility and prominence. From big data to precision medicine, the recent advances in biomedical research have swept away the conventional approach to medical science. The availability of large volumes of digitised clinical data, combined with powerful artificial intelligence (AI) algorithms, are proving to be the real gamechangers.

Kalkine Logo (PRNewsfoto/Kalkine Ltd.)

Get insights on Healthcare Innovations from three of our valued clients, who are leaders in the Australian healthcare and biotech space. Managing Director and Chief Executive Officer of Cynata Therapeutics Limited - Dr Ross Macdonald, Executive Chair and CEO of Invion Limited - Mr. Thian Chew, and CEO & Managing Director of PainChek Limited Mr. Philip Daffas.

The webinar will help potential investors get a sense of how the healthcare sector looks like in the future in an exclusive Invest Nest Webinar by Kalkine Media.

Cynata Therapeutics Limited is an Australian-based clinical-stage stem cell and regenerative medicine company, based in Cubitt Street, Cremorne, Victoria. The Company focusses on the development of therapies based on its unique Cymerus technology. The Company's Cymerus technology is addressing a critical limitation in existing MSCs (mesenchymal stem cells) production methods for therapeutic use.

Australian life sciences company Invion Limited is dedicated to transforming Photodynamic Therapy (PDT) to develop innovative and effective cancer treatments. The firm is leading the global clinical development of PhotosoftTM technology, which is an improved next-generation Photodynamic Therapy.

PainChek Limited engages in the development and commercialisation of mobile medical device applications. These device applications automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. The journey of PainChek began in 2016. Since then, PainChek has come a long way with several core goals achieved. PainChek envisions to emerge as a leader in the market for innovative pain assessment products while providing services to help enhance the quality of life for people suffering from pain.

About Kalkine Media
Kalkine Media operates across Australia, New Zealand, Canada, UK and the US. It aims to keep its readers abreast of the latest and trending news on the equity and commodity markets, the unravelling economy and other business developments.

Please register on- https://kalkinemedia.com/webinar/register/88308413557?utm_source=press_release&utm_medium=organic&utm_campaign=invest-nest-webinar-by-kalkine-media-healthcare-innovations-for-sustainable-future

Logo - https://mma.prnewswire.com/media/1341740/Kalkine_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2021 PR Newswire
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.